Last reviewed · How we verify
NCT01509560
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
Phase 2 trial testing Everolimus in Condition After Allogenic Peripheral Stem Cell Transplantation (SCT) in 21 participants. Completed in 30 April 2016.
30 April 2016
Quick facts
| Lead sponsor | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 1 November 2011 |
| Primary completion | 30 April 2016 |
| Estimated completion | 30 April 2016 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Everolimus (everolimus) — full drug profile →
Conditions studied
- Condition After Allogenic Peripheral Stem Cell Transplantation (SCT) — all drugs for Condition After Allogenic Peripheral Stem Cell Transplantation (SCT) →
Sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH — full company profile →
Who can join
18 and older, any sex, with Condition After Allogenic Peripheral Stem Cell Transplantation (SCT). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this prospective study is to examine whether the use of everolimus in patients after allogeneic SCT as part of GVHD prophylaxis for a further review in clinical studies is appropriate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01509560
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Everolimus
Trials testing the same drug.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07318324 — Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer · Phase 1 · not yet recruiting
- NCT07477548 — A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies · Phase 2 · not yet recruiting
- NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
- NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting
Other Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH trials
Trials by the same sponsor.
- NCT02335268 — Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thr · Phase 2 · completed
- NCT03622931 — Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines · Phase 2 · terminated
- NCT01320111 — Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment · Phase 2 · completed
- NCT01081431 — Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPS · Phase 2 · completed
- NCT01090089 — Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01509560 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- Last refreshed: 23 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01509560.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing